Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 13/20 | 0.38 |
| ▸ | JAK2 | O60674 | 13/20 | 0.38 |
| ▸ | JAK1 | P23458 | 1/20 | 0.38 |
| ▸ | NTRK1 | P04629 | 8/20 | 0.35 |
| ▸ | CDK2 | P24941 | 3/20 | 0.35 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.35 |
| ▸ | MUSK | O15146 | 1/20 | 0.35 |
| ▸ | LCK | P06239 | 1/20 | 0.35 |
| ▸ | RET | P07949 | 1/20 | 0.35 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.35 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.35 |
| ▸ | FLT3 | P36888 | 1/20 | 0.35 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.35 |
| ▸ | STAT5B | P51692 | 1/20 | 0.35 |
| ▸ | ALK | Q9UM73 | 3/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8512752 | 0.89 | JAK3 (0.39) | JAK3JAK2JAK1NTRK1CDK2 | |
| SCHEMBL8531250 | 0.88 | JAK2 (0.35) | JAK3JAK2JAK1NTRK1CDK2 | |
| SCHEMBL8531256 | 0.88 | JAK2 (0.35) | JAK3JAK2JAK1NTRK1CDK2 | |
| SCHEMBL9903474 | 0.85 | NTRK1 (0.46) | JAK3JAK2JAK1NTRK1CDK2 | |
| SCHEMBL9903898 | 0.81 | NTRK1 (0.39) | JAK3JAK2NTRK1CDK2AURKB | |
| SCHEMBL9903333 | 0.80 | NTRK1 (0.47) | JAK3JAK2JAK1NTRK1CDK2 | |
| SCHEMBL9903335 | 0.80 | NTRK1 (0.47) | JAK3JAK2JAK1NTRK1CDK2 | |
| SCHEMBL9902199 | 0.78 | ATR (0.35) | JAK3JAK2JAK1NTRK1CDK2 | |
| SCHEMBL9902207 | 0.78 | ATR (0.35) | JAK3JAK2JAK1NTRK1CDK2 | |
| SCHEMBL9905701 | 0.78 | ALK (0.44) | JAK3JAK2JAK1NTRK1CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9133200-B2 | Imidazo[1,2-b]pyridazine and imidazo[4,5-b]pyridine derivatives as JAK inhibitors | ALMIRALL, S.A. (ES) | 2015-09-15 | — | — | US | claimed |
| US-20130309200-A1 | IMIDAZO [1,2-B] PYRIDAZINE AND IMIDAZO [4,5-B] PYRIDINE DERIVATIVES AS JAK INHIBITORS | ALMIRALL, S.A. (ES) | 2013-11-21 | — | — | US | claimed |
| EP-2463289-A1 | Imidazo[1,2-b]pyridazine derivatives as JAK inhibitors | Almirall, S.A. (ES) | 2012-06-13 | — | — | EP | claimed |
| US-9133200-B2 | Imidazo[1,2-b]pyridazine and imidazo[4,5-b]pyridine derivatives as JAK inhibitors | ALMIRALL, S.A. (ES) | 2015-09-15 | — | — | US | disclosed |
| US-20130309200-A1 | IMIDAZO [1,2-B] PYRIDAZINE AND IMIDAZO [4,5-B] PYRIDINE DERIVATIVES AS JAK INHIBITORS | ALMIRALL, S.A. (ES) | 2013-11-21 | — | — | US | disclosed |
| EP-2463289-A1 | Imidazo[1,2-b]pyridazine derivatives as JAK inhibitors | Almirall, S.A. (ES) | 2012-06-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130309200-A1 | IMIDAZO [1,2-B] PYRIDAZINE AND IMIDAZO [4,5-B] PYRIDINE DERIVATIVES AS JAK INHIBITORS | JAK1, JAK2, JAK3 | JAK3 3/4885JAK2 2/4885JAK1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.